Related Experiment Video
Updated: Aug 15, 2026

Leveraging Turbidity and Thromboelastography for Complementary Clot Characterization
Published on: June 4, 2020
Abstract:
The use of the prothrombin complex products for the treatment of inhibitor patients is discussed in relation to our difficulty in identifying the effective therapeutic principle, as well as the factors responsible for thrombogenicity. It would appear that combination of factors is responsible for either or both therapeutic and thrombogenic phenomena. Possible intermediate or aggregate forms of the procoagulants are present in the products, protected from the neutralizing effects of antithrombin III.
More Related Videos
04:37Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation
Published on: May 23, 2025
08:50Thrombus Profiling Assay: A Microfluidics-Based Platform for Comprehensively Characterizing Biomechanical Thrombogenesis
Published on: January 9, 2026
Related Concept Videos
Complexometric EDTA Titration Curves
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Clot Retraction and Fibrinolysis
Venous Thrombosis III: Interprofessional Care